Prices are updated after-hours

Manufacturing 1

ComSovereign Holding Corp

COMS | $0.2001 -23.04% 37.35% 420

(0.0% 1d) (35.1% 1m) (-86.7% 1y) (0.0% 2d) (20.0% 3d) (0.0% 7d) (-72.1% volume)
Earnings Calendar:
Market Cap: $ 539,317
https://www.comsovereign.com/
Sec Filling | Patents | 112 employees

(US) COMSovereign Holding Corp. (Nasdaq: COMS) has assembled a portfolio of communications technology companies that enhance connectivity across the entire data transmission spectrum. Through strategic acquisitions and organic research and development efforts, COMSovereign has become a U.S.-based communications provider able to provide 4G LTE Advanced and 5G-NR telecom solutions to network operators and enterprises.

acquisitions communication 5g

add to watch list Paper trade email alert is off

ATAI Life Sciences N.V.

ATAI | $1.87 -5.08% -5.07% 840K

Manufacturing

(0.0% 1d) (8.1% 1m) (0.0% 1y) (0.0% 2d) (-5.6% 3d) (1.1% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 313,061,669
https://www.atai.life
Sec Filling | Patents | 35 employees

(DE) atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London.

treatment profitable msa

add to watch list Paper trade email alert is off

Femasys Inc

FEMY | $1.33 0.0% 110K

Manufacturing

(0.0% 1d) (-11.3% 1m) (59.9% 1y) (0.0% 2d) (0.0% 3d) (0.8% 7d) (-59.59% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 29,392,132

Sec Filling | Patents | 35 employees

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

contraception food

add to watch list Paper trade email alert is off

ATI Physical Therapy Inc - Class A

ATIP | News | $4.0601 0.25% 0.0% 980

Manufacturing

(0.0% 1d) (-31.8% 1m) (-70.6% 1y) (0.0% 2d) (0.2% 3d) (0.7% 7d) (-73.9% volume)
Earnings Calendar:
Market Cap: $ 17,094,182

Sec Filling | Patents | 4 employees

Fortress Value Acquisition Corp. II is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

acquisitions

add to watch list Paper trade email alert is off

Cyteir Therapeutics Inc

CYT | $3.02 2.65% 1M

Manufacturing

(0.0% 1d) (0.0% 1m) (40.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (342.66% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 108,714,165
https://cyteir.com
Sec Filling | Patents | 31 employees

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

cancer

add to watch list Paper trade email alert is off

Altamira Therapeutics Ltd

CYTO | $1.44 -8.86% -5.69% 3M

Manufacturing

(0.0% 1d) (-40.5% 1m) (38.5% 1y) (0.0% 2d) (-8.9% 3d) (2.1% 7d) (2607.94% volume)
Earnings Calendar:
Market Cap: $ 3,225,953
http://www.aurismedical.com/
Sec Filling | Patents | 9 employees

(CH) Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'

treatment pathogens

add to watch list Paper trade email alert is off

Amplitech Group Inc

AMPG | $2.26 -5.04% -3.93% 43K

Manufacturing

(0.0% 1d) (16.5% 1m) (-24.3% 1y) (0.0% 2d) (-5.0% 3d) (-1.7% 7d) (322.71% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 21,960,675
https://www.amplitechinc.com
Sec Filling | Patents | 16 employees

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, Defense and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Its steady growth over the past 13+ years has come about because AmpliTech can provide complex, custom solutions for nearly ANY custom requirements that are presented. In addition, AmpliTech has the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs.

military defense

add to watch list Paper trade email alert is off

Novo Integrated Sciences Inc

NVOS | $0.525 1.94% 2.18% 450K

Manufacturing

(0.0% 1d) (14.7% 1m) (381.8% 1y) (0.0% 2d) (1.9% 3d) (17.8% 7d) (-63.77% volume)
Earnings Calendar:
Market Cap: $ 10,003,625
https://www.novointegrated.com
Sec Filling | Patents | 92 employees

Novo Integrated Sciences, Inc. is a U.S. based provider of multidisciplinary primary care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science. The company believes that “decentralizing” healthcare, through the integration of medical technology and interconnectivity offers an essential solution to the fundamental transformation of healthcare delivery. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost- effective healthcare distribution. Currently, the Company’s revenue is generated solely through NHL’s team of multidisciplinary primary health care clinicians and practitioners providing assessment, diagnosis, treatment, pain management, rehabilitation, education and primary prevention for a wide array of orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations through NHL’s 16 corporate-owned clinics, a contracted network of affiliate clinics, and eldercare related long-term care homes, retirement homes, and community-based locations in Canada. Its specialized multidisciplinary primary health care services include, but are not limited to, physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy (including pre- and post-partum), acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women’s pelvic health programs, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning programs including event and game coverage, and private personal training.

diagnostics women treatment education games

add to watch list Paper trade email alert is off

Aveanna Healthcare Holdings Inc

AVAH | $2.31 1.76% 2.78% 95K

Manufacturing

(0.0% 1d) (-1.3% 1m) (102.6% 1y) (0.0% 2d) (1.8% 3d) (0.9% 7d) (141.38% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 444,394,822
https://www.aveanna.com
Sec Filling | Patents | 2021 employees

Based in Atlanta, Georgia, Aveanna is a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations. Aveanna directly addresses the most pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home, the lower cost care setting preferred by patients.

add to watch list Paper trade email alert is off

Cricut Inc - Class A

CRCT | $5.31 0.38% 0.47% 470K

Manufacturing

(0.0% 1d) (15.7% 1m) (-39.2% 1y) (0.0% 2d) (0.4% 3d) (0.8% 7d) (-21.87% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 268,625,020
https://cricut.com
Sec Filling | Patents | n/a employees

Cricut Inc. is a creative technology platform company dedicated to encouraging new ways for people to experience making at home. As an empowering lifestyle brand, Cricut’s mission is to unleash the creative potential of its users with innovations that bring ideas to life in the form of professional-looking, personalized handmade projects. Cricut’s industry-leading products include its flagship line of smart cutting machines—Cricut Maker®, the Cricut Explore® family, and Cricut Joy®— accompanied by other unique tools like Cricut EasyPress®, the Infusible Ink™ system, and a diverse collection of materials. In addition to Cricut’s core offerings, the brand also fosters a thriving community of more than four million dedicated users worldwide.

brands

add to watch list Paper trade email alert is off

Ikena Oncology Inc

IKNA | $1.29 -4.44% -3.05% 150K

Manufacturing

(0.0% 1d) (-7.2% 1m) (-74.0% 1y) (0.0% 2d) (-4.4% 3d) (-3.0% 7d) (-41.64% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 62,252,963
https://www.ikenaoncology.com
Sec Filling | Patents | 67 employees

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.

cancer

add to watch list Paper trade email alert is off

NeuroPace Inc

NPCE | $13.56 -3.21% -3.59% 44K

Manufacturing

(0.0% 1d) (1.7% 1m) (202.0% 1y) (0.0% 2d) (-3.2% 3d) (-3.0% 7d) (-70.94% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 389,441,003
https://www.neuropace.com
Sec Filling | Patents | 167 employees

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy, and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

education treatment

add to watch list Paper trade email alert is off

Nuwellis Inc

NUWE | $0.2521 -14.95% -18.51% 1.9M

Manufacturing

(0.0% 1d) (-39.0% 1m) (-94.5% 1y) (0.0% 2d) (-16.7% 3d) (-3.8% 7d) (-47.18% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,714,644
https://www.nuwellis.com
Sec Filling | Patents | 15027 employees

(US) Nuwellis, Inc. , formally CHF Solutions, is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions

brands

add to watch list Paper trade email alert is off

Nuvve Holding Corp

NVVE | News | $0.729 0.14% -1.75% 26K

Manufacturing

(0.0% 1d) (-22.7% 1m) (32.7% 1y) (0.0% 2d) (0.0% 3d) (5.8% 7d) (-58.7% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 4,424,967
https://nuvve.com
Sec Filling | Patents | 21 employees

Nuvve is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. Its mission is to lower the cost of electric vehicle ownership while supporting the integration of renewable energy sources, including solar and wind. Nuvve’s Grid Integrated Vehicle, GIVe™, platform is refueling the next generation of electric vehicle fleets through intelligent, bidirectional charging solutions. Since its founding in 2010, Nuvve has launched successful V2G projects on five continents and is deploying commercial services worldwide by developing partnerships with utilities, automakers, and electric vehicle fleets

energy electric vehicles solar vehicles renewable eletrical

add to watch list Paper trade email alert is off

Privia Health Group Inc

PRVA | $18.17 -3.35% -3.52% 1M

Manufacturing

(0.0% 1d) (-4.2% 1m) (-30.8% 1y) (0.0% 2d) (-3.4% 3d) (0.5% 7d) (20.19% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,155,971,162
https://www.priviahealth.com
Sec Filling | Patents | 964 employees

Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. iTS platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers.

education optical

add to watch list Paper trade email alert is off

Garrett Motion Inc - New

GTX | $9.85 1.23% 1.12% 700K

Manufacturing

(0.0% 1d) (1.0% 1m) (20.9% 1y) (0.0% 2d) (1.2% 3d) (5.3% 7d) (29.27% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 2,238,036,388
https://www.garrettmotion.com/
Sec Filling | Patents | 3 employees

(CH) Garrett Motion is a differentiated technology leader, serving customers worldwide for more than 65 years with passenger vehicle, commercial vehicle, aftermarket replacement and performance enhancement solutions. Garrett’s cutting-edge technology enables vehicles to become safer, more connected, efficient and environmentally friendly. The Company's portfolio of turbocharging, electric boosting and automotive software solutions empowers the transportation industry to redefine and further advance motion.

automotive eletrical vehicles

add to watch list Paper trade email alert is off

The Honest Company Inc

HNST S | $3.06 -1.61% -1.63% 460K

Manufacturing

(0.0% 1d) (-21.9% 1m) (84.3% 1y) (0.0% 2d) (-1.6% 3d) (1.0% 7d) (-14.55% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 296,920,328
https://www.honest.com
Sec Filling | Patents | 191 employees

The Honest Company is a mission-driven, digitally-native brand focused on leading the clean lifestyle movement, creating a community for conscious consumers and seeking to disrupt multiple consumer product categories.

brands

add to watch list Paper trade email alert is off

Biotricity Inc

BTCY | $1.39 -4.14% -5.45% 150K

Manufacturing

(0.0% 1d) (4.5% 1m) (-55.4% 1y) (0.0% 2d) (-4.1% 3d) (3.0% 7d) (-21.54% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 12,869,950
https://biotricity.com
Sec Filling | Patents | 24 employees

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets.

diagnostics

add to watch list Paper trade email alert is off

PetVivo Holdings Inc

PETV 4 | $0.7882 -6.17% -2.15% 29K

Manufacturing

(0.0% 1d) (-23.3% 1m) (-69.7% 1y) (0.0% 2d) (-6.0% 3d) (8.2% 7d) (21.77% volume)
Earnings Calendar: 2022-06-09
Market Cap: $ 13,218,128
https://petvivo.com
Sec Filling | Patents | 2 employees

PetVivo Holdings, Inc. is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

treatment injection animals

add to watch list Paper trade email alert is off

Ethan Allen Interiors, Inc.

ETD | News | $33.41 -1.88% 0.0% 270K

Manufacturing

(0.0% 1d) (-0.1% 1m) (26.7% 1y) (0.0% 2d) (-1.9% 3d) (5.0% 7d) (4.6% volume)
Earnings Calendar: 2024-01-24
Market Cap: $ 848,600,202
https://www.ethanallen.com
Sec Filling | Patents | 3369 employees

Ethan Allen Interiors Inc. is a leading interior design company, manufacturer and retailer in the home furnishings marketplace. The Company provides complimentary interior design service to its clients and sells a full range of furniture products and decorative home accents through a retail network of approximately 300 design centers in the United States and abroad as well as online at ethanallen.com. Ethan Allen owns and operates nine manufacturing facilities, including six manufacturing plants in the United States, two manufacturing plants in Mexico and one manufacturing plant in Honduras. Approximately 75% of its products are manufactured or assembled in these North American facilities.

add to watch list Paper trade email alert is off